A Phase 2, Open-Label Extension, Efficacy and Safety Study of a RARγ Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)

Trial Profile

A Phase 2, Open-Label Extension, Efficacy and Safety Study of a RARγ Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Apr 2017

At a glance

  • Drugs Palovarotene (Primary)
  • Indications Fibrodysplasia ossificans progressiva
  • Focus Therapeutic Use
  • Sponsors Clementia Pharmaceuticals
  • Most Recent Events

    • 28 Mar 2017 Preliminary results (n = 40) from Part A of the Open Label Extension (OLE) study published in a Clementia Pharmaceuticals media release.
    • 10 Feb 2017 Planned number of patients changed from 60 to 58.
    • 10 Feb 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top